Tip 2 Diyabet için Global Rehber - International Diabetes Federation

Kardiyovasküler risk
10. Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR.
UKPDS 56: The UKPDS Risk Engine: a model for the risk
of coronary heart disease in type 2 diabetes. Clin Sci
2001; 101: 671-79.
11. ETDRS Investigators. Aspirin effects on mortality and
morbidity in patients with diabetes mellitus. Early
Treatment Diabetic Retinopathy Study report 14. JAMA
1992; 268: 1292-300.
12. Hansson L, Zanchetti A, Carruthers SG, Dahlof B,
Elmfeldt D, Julius S, et al. Effects of intensive bloodpressure
lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension
Optimal Treatment (HOT) randomised trial. Lancet 1998;
351: 1755-62.
13. Eccles M, Freemantle N, Mason J. North of England
evidence based guidelines development project:
Evidence based clinical practice guideline: aspirin for
the secondary prophylaxis of vascular disease in primary
care. BMJ 1998; 316: 1303-09.
14. Antithrombotic Trialists’ Collaboration. Collaborative
meta-analysis of randomised trials of antiplatelet therapy
for prevention of death, myocardial infarction, and stroke
in high risk patients. BMJ 2002; 324: 71-86.
15. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H,
Pedersen O. Multifactorial intervention and
cardiovascular disease in patients with Type 2 diabetes.
N Engl J Med 2003; 348: 383-93.
52 Tip 2 Diyabet için Global Rehber